Progress in Medicinal Chemistry - 1st Edition - ISBN: 9780128211731

Progress in Medicinal Chemistry, Volume 59

1st Edition

0.0 star rating Write a review
Editors: David Witty Brian Cox
Hardcover ISBN: 9780128211731
Imprint: Elsevier
Published Date: 1st June 2020
Page Count: 260
Sales tax will be calculated at check-out Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

1. Small Molecules - Giant Leaps for Immuno-Oncology
Klaus Urbahns
2. Reviewing P2X7
Christine Gelin
3. Reviewing ASK1
David Amantini
4. Reviewing DNA-encoded libraries
Carlos Azevedo


Description

Progress in Medicinal Chemistry, Volume 59, provides a review of eclectic developments in medicinal G139 chemistry. Each chapter is written by an international board of authors, with this release focusing on Small Molecules - Giant Leaps for Immuno-Oncology, Reviewing P2X7, Reviewing ASK1, and Reviewing DNA-encoded libraries.

Key Features

  • Provides extended, timely reviews of topics in medicinal chemistry
  • Contains targets and technologies relevant to the discovery of tomorrow’s drugs
  • Presents analyses of successful drug discovery programs

Readership

Everyone interested in the strategy and practice of the preclinical phases of the creation of new medicines. Those wishing to understand the drivers of drug design or expand their knowledge of therapeutic target classes


Details

No. of pages:
260
Language:
English
Copyright:
© Elsevier 2020
Published:
1st June 2020
Imprint:
Elsevier
Hardcover ISBN:
9780128211731

Ratings and Reviews


About the Editors

David Witty

David Witty Editor

Dr David Witty has more than 20 years experience in the pharmaceutical industry as a medicinal chemist and project leader working principally in areas of anti-infectives, metabolic diseases, cognition and pain, delivering clinical candidates for several conditions. He led IT Strategy within the Neurology division of GSK, developing and deploying the first Electronic Notebooks for drug discovery to sites in the UK and Singapore. He has contributed more than 90 scientific papers, reviews, patents and books on medicinal and synthetic chemistry.

In 2010 David and several colleagues successfully raised $35M in venture funding to found Convergence Pharmaceuticals, a specialist ion channel company focused on the development of novel treatments for pain, based in Cambridge UK. David presently leads their discovery programme and manages scientific operations within the business.

David is chairman of the Fine Chemicals Group of the Society of Chemical Industry, with responsibility for the delivery of conferences, seminars and training courses for chemists throughout the UK and Europe, and advising parliamentary bodies on matters of relevance to the UK chemical industry.

Since 2008 David has been a STEM ambassador for SETPOINT, introducing school students at both primary and secondary level to the excitement and possibilities of pursuing scientific careers, through workshops, lectures and competitions.

Affiliations and Expertise

WITNET LTD, Cambridge, UK

Brian Cox Editor

Professor Brian Cox is at University of Sussex, Brighton, UK

Affiliations and Expertise

University of Sussex, Brighton, UK